Underexpression of peroxisome proliferator-activated receptor (PPAR)γ in PAX8/PPARγ-negative thyroid tumours

被引:0
|
作者
A R Marques
C Espadinha
M J Frias
L Roque
A L Catarino
L G Sobrinho
V Leite
机构
[1] Centro de Investigação de Patobiologia Molecular,
[2] Instituto Português de Oncologia Francisco Gentil,undefined
[3] Rua Professor Lima Basto,undefined
[4] Departamento de Patologia Morfológica,undefined
[5] Instituto Português de Oncologia Francisco Gentil,undefined
[6] Rua Professor Lima Basto,undefined
来源
British Journal of Cancer | 2004年 / 91卷
关键词
PPAR; PAX8; underexpression; follicular thyroid tumours;
D O I
暂无
中图分类号
学科分类号
摘要
The expression of peroxisome proliferator-activated receptor (PPAR)γ in thyroid neoplasias and in normal thyroid (NT) tissues has not been fully investigated. The objectives of the present work were: to study and compare the relative expression of PPARγ in normal, benign and malignant thyroid tissues and to correlate PPARγ immunostaining with clinical/pathological features of patients with thyroid cancer. We analysed the expression of PPARγ in several types of thyroid tissues by reverse transcription–polymerase chain reaction (RT–PCR), interphase fluorescent in situ hybridisation, real-time RT–PCR and immunohistochemistry. We have demonstrated that NT tissues express PPARγ both at mRNA and at protein level. PAX8-PPARγ fusion gene expression was found in 25% (six of 24) of follicular thyroid carcinomas (FTCs) and in 17% (six of 36) of follicular thyroid adenomas, but in none of the 10 normal tissues, 28 nodular hyperplasias, 38 papillary thyroid carcinomas (PTCs) and 11 poorly differentiated thyroid carcinomas (PDTCs). By real-time RT–PCR, we observed that tumours negative for the PAX8-PPARγ rearrangement expressed lower levels of PPARγ mRNA than the NT. Overexpression of PPARγ transcripts was detected in 80% (four of five) of translocation-positive tumours. Diffuse nuclear staining was significantly (P<0.05) less prevalent in FTCs (53%; 18 of 34), PTCs (49%; 19 of 39) and PDTCs (0%; zero of 13) than in normal tissue (77%; 36 of 47). Peroxisome proliferator-activated receptorγ-negative FTCs were more likely to be locally invasive, to persist after surgery, to metastasise and to have poorly differentiated areas. Papillary thyroid carcinomas with a predominantly follicular pattern were more often PPARγ negative than classic PTCs (80% vs 28%; P=0.01). Our results demonstrated that PPARγ is underexpressed in translocation-negative thyroid tumours of follicular origin and that a further reduction of PPARγ expression is associated with dedifferentiation at later stages of tumour development and progression.
引用
收藏
页码:732 / 738
页数:6
相关论文
共 50 条
  • [1] Underexpression of peroxisome proliferator-activated receptor (PPAR)γ in PAX8/PPARγ-negative thyroid tumours
    Marques, AR
    Espadinha, C
    Frias, MJ
    Roque, L
    Catarino, AL
    Sobrinho, LG
    Leite, V
    BRITISH JOURNAL OF CANCER, 2004, 91 (04) : 732 - 738
  • [2] Peroxisome proliferator-activated receptor (PPAR) modulators: Diabetes and beyond
    Jones, AB
    MEDICINAL RESEARCH REVIEWS, 2001, 21 (06) : 540 - 552
  • [3] Activation of human peroxisome proliferator-activated receptor (PPAR) subtypes by pioglitazone
    Sakamoto, J
    Kimura, H
    Moriyama, S
    Odaka, H
    Momose, Y
    Sugiyama, Y
    Sawada, H
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2000, 278 (03) : 704 - 711
  • [4] Oleamide activates peroxisome proliferator-activated receptor gamma (PPARγ) in vitro
    Mauro Dionisi
    Stephen PH Alexander
    Andrew J Bennett
    Lipids in Health and Disease, 11
  • [5] Oleamide activates peroxisome proliferator-activated receptor gamma (PPARγ) in vitro
    Dionisi, Mauro
    Alexander, Stephen P. H.
    Bennett, Andrew J.
    LIPIDS IN HEALTH AND DISEASE, 2012, 11
  • [6] Role of the peroxisome proliferator-activated receptors (PPAR) in atherosclerosis
    Neve, BP
    Fruchart, JC
    Staels, B
    BIOCHEMICAL PHARMACOLOGY, 2000, 60 (08) : 1245 - 1250
  • [7] Peroxisome proliferator-activated receptors (PPAR). Antiproliferative properties
    Hojka, Anna
    Rapak, Andrzej
    POSTEPY HIGIENY I MEDYCYNY DOSWIADCZALNEJ, 2011, 65 : 404 - 413
  • [8] PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR (PPAR) - STRUCTURE, MECHANISMS OF ACTIVATION AND DIVERSE FUNCTIONS
    MOTOJIMA, K
    CELL STRUCTURE AND FUNCTION, 1993, 18 (05) : 267 - 277
  • [9] Novel biphenylcarboxylic acid peroxisome proliferator-activated receptor (PPAR) δ selective antagonists
    Kasuga, Jun-ichi
    Ishida, Seiichi
    Yamasaki, Daisuke
    Makishima, Makoto
    Doi, Takefumi
    Hashimoto, Yuichi
    Miyachi, Hiroyuki
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2009, 19 (23) : 6595 - 6599
  • [10] The role of peroxisome proliferator-activated receptors (PPAR) in immune responses
    Christofides, Anthos
    Konstantinidou, Eirini
    Jani, Chinmay
    Boussiotis, Vassiliki A.
    METABOLISM-CLINICAL AND EXPERIMENTAL, 2021, 114